- Home
- IGMS vs CRVO Comparison
IGMS vs CRVO Comparison
Compare IGMS & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- CRVO
- Stock Information
- Founded
- IGMS 1993
- CRVO 2001
- Country
- IGMS United States
- CRVO United States
- Employees
- IGMS N/A
- CRVO N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- CRVO Biotechnology: Pharmaceutical Preparations
- Sector
- IGMS Health Care
- CRVO Health Care
- Exchange
- IGMS Nasdaq
- CRVO Nasdaq
- Market Cap
- IGMS 82.1M
- CRVO 95.4M
- IPO Year
- IGMS 2019
- CRVO N/A
- Fundamental
- Price
- IGMS $1.24
- CRVO $9.48
- Analyst Decision
- IGMS Hold
- CRVO Strong Buy
- Analyst Count
- IGMS 8
- CRVO 8
- Target Price
- IGMS $6.14
- CRVO $25.43
- AVG Volume (30 Days)
- IGMS 198.4K
- CRVO 13.7M
- Earning Date
- IGMS 03-06-2025
- CRVO 03-17-2025
- Dividend Yield
- IGMS N/A
- CRVO N/A
- EPS Growth
- IGMS N/A
- CRVO N/A
- EPS
- IGMS N/A
- CRVO N/A
- Revenue
- IGMS $2,679,000.00
- CRVO $9,737,974.00
- Revenue This Year
- IGMS $134.71
- CRVO N/A
- Revenue Next Year
- IGMS $74.27
- CRVO N/A
- P/E Ratio
- IGMS N/A
- CRVO N/A
- Revenue Growth
- IGMS 25.77
- CRVO 36.29
- 52 Week Low
- IGMS $1.15
- CRVO $1.80
- 52 Week High
- IGMS $22.50
- CRVO $25.92
- Technical
- Relative Strength Index (RSI)
- IGMS 37.38
- CRVO 61.07
- Support Level
- IGMS $1.17
- CRVO $7.13
- Resistance Level
- IGMS $1.31
- CRVO $10.72
- Average True Range (ATR)
- IGMS 0.09
- CRVO 2.50
- MACD
- IGMS 0.05
- CRVO 0.07
- Stochastic Oscillator
- IGMS 32.14
- CRVO 50.33
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.